A new trading day began on Monday, with Arrowhead Pharmaceuticals Inc (NASDAQ: ARWR) stock price up 7.21% from the previous day of trading, before settling in for the closing price of $13.03. ARWR’s price has ranged from $9.57 to $30.41 over the past 52 weeks.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
A company in the Healthcare sector has dropped its sales by -2.87% annually for the last half of the decade. Meanwhile, its annual earnings per share averaged 65.01%. With a float of $114.31 million, this company’s outstanding shares have now reached $125.57 million.
In an organization with 609 employees, it is important to assess its efficiency. In terms of profitability, gross margin is -481.68%, operating margin of -25037.88%, and the pretax margin is -25955.44%.
Arrowhead Pharmaceuticals Inc (ARWR) Insider Updates
As we move forward, let’s examine how large-scale investors are investing in this stock of the Biotechnology Industry. The insider ownership of Arrowhead Pharmaceuticals Inc is 16.75%, while institutional ownership is 74.86%. The most recent insider transaction that took place on Apr 11 ’25, was worth 583,692. In this transaction Chief Executive Officer of this company sold 50,800 shares at a rate of $11.49, taking the stock ownership to the 3,921,255 shares. Before that another transaction happened on Apr 10 ’25, when Company’s Chief Executive Officer sold 50,000 for $10.87, making the entire transaction worth $543,500. This insider now owns 3,972,055 shares in total.
Arrowhead Pharmaceuticals Inc (ARWR) Performance Highlights and Predictions
Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.55 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 65.01% per share during the next fiscal year.
Arrowhead Pharmaceuticals Inc (NASDAQ: ARWR) Trading Performance Indicators
Here are Arrowhead Pharmaceuticals Inc’s current performance indicators. According to the last quarter’s results, the stock had a quick ratio of 6.09. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 767.34.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -5.15, a number that is poised to hit -0.90 in the next quarter and is forecasted to reach -3.82 in one year’s time.
Technical Analysis of Arrowhead Pharmaceuticals Inc (ARWR)
Let’s dig in a bit further. During the last 5-days, its volume was 1.59 million. That was inferior than the volume of 1.92 million it reported in year-ago period. As of the previous 9 days, the stock’s Stochastic %D was 38.60%. Additionally, its Average True Range was 0.97.
During the past 100 days, Arrowhead Pharmaceuticals Inc’s (ARWR) raw stochastic average was set at 34.11%, which indicates a significant decrease from 60.47% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 51.93% in the past 14 days, which was lower than the 70.32% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $13.76, while its 200-day Moving Average is $19.35. However, in the short run, Arrowhead Pharmaceuticals Inc’s stock first resistance to watch stands at $14.44. Second resistance stands at $14.91. The third major resistance level sits at $15.42. If the price goes on to break the first support level at $13.46, it is likely to go to the next support level at $12.95. Assuming the price breaks the second support level, the third support level stands at $12.48.
Arrowhead Pharmaceuticals Inc (NASDAQ: ARWR) Key Stats
With a market capitalization of 1.92 billion, the company has a total of 137,317K Shares Outstanding. Currently, annual sales are 3,550 K while annual income is -599,490 K. The company’s previous quarter sales were 2,500 K while its latest quarter income was -173,090 K.
